PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT o 2.1 Preface o 2.2 Preface o 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE o Market ecosystem o Parent market o Market characteristics o Market segmentation analysis o Value chain analysis PART 04: MARKET SIZING o Market definition o Market sizing 2019 o Market size and forecast 2019-2024 o Market outlook PART 05: FIVE FORCES ANALYSIS o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition PART 06: MARKET SEGMENTATION BY PRODUCT o Market segmentation by product o Comparison by product o Low-molecular-weight heparin - Market size and forecast 2019-2024 o Others - Market size and forecast 2019-2024 o Market opportunity by product PART 07: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION o Market segmentation by route of administration o Comparison by route of administration o Subcutaneous injection - Market size and forecast 2019-2024 o Intravenous/infusion - Market size and forecast 2019-2024 o Market opportunity by route of administration PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE o Geographic segmentation o Geographic comparison o Europe - Market size and forecast 2019-2024 o North America - Market size and forecast 2019-2024 o Asia - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES o Market drivers o Market challenges PART 12: MARKET TRENDS o Increasing R&D activities and new therapeutic applications of heparin o Advent of biosimilar low-molecular-weight heparin o Development of drugs to remove heparin after surgery PART 13: VENDOR LANDSCAPE o Overview o Landscape disruption o Competitive scenario PART 14: VENDOR ANALYSIS o Vendors covered o Vendor classification o Market positioning of vendors o Aspen Pharmacare Holdings Ltd. o Baxter International Inc. o Eisai Co. Ltd. o Fresenius SE & Co. KGaA o Hikma Pharmaceuticals Plc o Laboratorios Farmaceuticos Rovi SA  o Mylan NV o Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. o Pfizer Inc. o Sanofi PART 15: APPENDIX o Research methodology o List of abbreviations o Definition of market positioning of vendors PART 16: EXPLORE TECHNAVIO Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Product overview Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2019 Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions) Exhibit 09: Global market: Year-over-year growth 2020-2024 (%) Exhibit 10: Five forces analysis 2019 Exhibit 11: Five forces analysis 2024 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2019 Exhibit 18: Product - Market share 2019-2024 (%) Exhibit 19: Comparison of product Exhibit 20: Low-molecular-weight heparin - Market size and forecast 2019-2024 ($ millions) Exhibit 21: Low-molecular-weight heparin - Year-over-year growth 2020-2024 (%) Exhibit 22: Others - Market size and forecast 2019-2024 ($ millions) Exhibit 23: Others - Year-over-year growth 2020-2024 (%) Exhibit 24: Market opportunity by product Exhibit 25: Route of administration - Market share 2019-2024 (%) Exhibit 26: Comparison by route of administration Exhibit 27: Subcutaneous injection - Market size and forecast 2019-2024 ($ millions) Exhibit 28: Subcutaneous injection - Year-over-year growth 2020-2024 (%) Exhibit 29: Intravenous/infusion - Market size and forecast 2019-2024 ($ millions) Exhibit 30: Intravenous/infusion - Year-over-year growth 2020-2024 (%) Exhibit 31: Market opportunity by route of administration Exhibit 32: Customer landscape Exhibit 33: Market share by geography 2019-2024 (%) Exhibit 34: Geographic comparison Exhibit 35: Europe - Market size and forecast 2019-2024 ($ millions) Exhibit 36: Europe - Year-over-year growth 2020-2024 (%) Exhibit 37: North America - Market size and forecast 2019-2024 ($ millions) Exhibit 38: North America - Year-over-year growth 2020-2024 (%) Exhibit 39: Asia - Market size and forecast 2019-2024 ($ millions) Exhibit 40: Asia - Year-over-year growth 2020-2024 (%) Exhibit 41: ROW - Market size and forecast 2019-2024 ($ millions) Exhibit 42: ROW - Year-over-year growth 2020-2024 (%) Exhibit 43: Key leading countries Exhibit 44: Market opportunity Exhibit 45: Decision framework Exhibit 46: Impact of drivers and challenges Exhibit 47: Vendor landscape Exhibit 48: Landscape disruption Exhibit 49: Vendors covered Exhibit 50: Vendor classification Exhibit 51: Market positioning of vendors Exhibit 52: Aspen Pharmacare Holdings Ltd. - Vendor overview Exhibit 53: Aspen Pharmacare Holdings Ltd. - Business segments Exhibit 54: Aspen Pharmacare Holdings Ltd. - Organizational developments Exhibit 55: Aspen Pharmacare Holdings Ltd. - Geographic focus Exhibit 56: Aspen Pharmacare Holdings Ltd. - Segment focus Exhibit 57: Aspen Pharmacare Holdings Ltd. - Key offerings Exhibit 58: Aspen Pharmacare Holdings Ltd. - Key customers Exhibit 59: Baxter International Inc. - Vendor overview Exhibit 60: Baxter International Inc. - Business segments Exhibit 61: Baxter International Inc. - Organizational developments Exhibit 62: Baxter International Inc. - Geographic focus Exhibit 63: Baxter International Inc. - Segment focus Exhibit 64: Baxter International Inc. - Key offerings Exhibit 65: Baxter International Inc. - Key customers Exhibit 66: Eisai Co. Ltd. - Vendor overview Exhibit 67: Eisai Co. Ltd. - Business segments Exhibit 68: Eisai Co. Ltd. - Organizational developments Exhibit 69: Eisai Co. Ltd. - Geographic focus Exhibit 70: Eisai Co. Ltd. - Segment focus Exhibit 71: Eisai Co. Ltd. - Key offerings Exhibit 72: Eisai Co. Ltd. - Key customers Exhibit 73: Fresenius SE & Co. KGaA - Vendor overview Exhibit 74: Fresenius SE & Co. KGaA - Business segments Exhibit 75: Fresenius SE & Co. KGaA - Organizational developments Exhibit 76: Fresenius SE & Co. KGaA - Geographic focus Exhibit 77: Fresenius SE & Co. KGaA - Segment focus Exhibit 78: Fresenius SE & Co. KGaA - Key offerings Exhibit 79: Fresenius SE & Co. KGaA - Key customers Exhibit 80: Hikma Pharmaceuticals Plc - Vendor overview Exhibit 81: Hikma Pharmaceuticals Plc - Business segments Exhibit 82: Hikma Pharmaceuticals Plc - Organizational developments Exhibit 83: Hikma Pharmaceuticals Plc - Geographic focus Exhibit 84: Hikma Pharmaceuticals Plc - Segment focus Exhibit 85: Hikma Pharmaceuticals Plc - Key offerings Exhibit 86: Hikma Pharmaceuticals Plc - Key customers Exhibit 87: Laboratorios Farmaceuticos Rovi SA  - Vendor overview Exhibit 88: Laboratorios Farmaceuticos Rovi SA  - Business segments Exhibit 89: Laboratorios Farmaceuticos Rovi SA  - Organizational developments Exhibit 90: Laboratorios Farmaceuticos Rovi SA  - Segment focus Exhibit 91: Laboratorios Farmaceuticos Rovi SA  - Key offerings Exhibit 92: Laboratorios Farmaceuticos Rovi SA  - Key customers Exhibit 93: Mylan NV - Vendor overview Exhibit 94: Mylan NV - Product segments Exhibit 95: Mylan NV - Organizational developments Exhibit 96: Mylan NV - Geographic focus Exhibit 97: Mylan NV - Segment focus Exhibit 98: Mylan NV - Key offerings Exhibit 99: Mylan NV - Key customers Exhibit 100: Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. - Vendor overview Exhibit 101: Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. - Product segments Exhibit 102: Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. - Organizational developments Exhibit 103: Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. - Key offerings Exhibit 104: Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. - Key customers Exhibit 105: Pfizer Inc. - Vendor overview Exhibit 106: Pfizer Inc. - Business segments Exhibit 107: Pfizer Inc. - Organizational developments Exhibit 108: Pfizer Inc. - Geographic focus Exhibit 109: Pfizer Inc. - Segment focus Exhibit 110: Pfizer Inc. - Key offerings Exhibit 111: Pfizer Inc. - Key customers Exhibit 112: Sanofi - Vendor overview Exhibit 113: Sanofi - Business segments Exhibit 114: Sanofi - Organizational developments Exhibit 115: Sanofi - Geographic focus Exhibit 116: Sanofi - Segment focus Exhibit 117: Sanofi - Key offerings Exhibit 118: Sanofi - Key customers Exhibit 119: Validation techniques employed for market sizing Exhibit 120: Definition of market positioning of vendors

Aspen Pharmacare Holdings Ltd., Baxter International Inc., Eisai Co. Ltd., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi SA, Mylan NV, Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi.